Search Results - james+barrow

3 Results

Sort By:

Gut-specific serotonin transporter inhibitors for treatment of constipation

Value Proposition· Potent inhibition of serotonin transporter (SERT) in GI system· Luminally and or/peripherally-restricted SERT inhibitors· Result in enhanced action of serotonin in stimulation of GI motility· Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...

Published: 3/13/2025 | Inventor(s): Pankaj Pasricha, James Barrow, Qian Li, Pablo de Leon, Yifang Huang

Keywords(s): Antagonists/Inhibitors, Biomarker, Disease Indication, Gastrointestinal Disorders, Mechanism-of-action Biomarker, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology

Non-acid IP6K Inhibitors

Unmet Need Globally, in 2021, there were approximately 537 million cases of diabetes which resulted in about 6.7 million deaths and $966 billion of healthcare expenditure (IDF). About 95% of diabetes cases are type 2 diabetes (T2D), which is characterized by either impaired insulin production or insulin resistance, and primarily occurs in adults. There...

Published: 3/14/2025 | Inventor(s): Tyler Heitmann, James Barrow

Keywords(s):

Category(s): Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets

Design, Synthesis and Structure-activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors

This invention describes a set of novel small molecules that inhibit RNA polymerase I. RNA polymerase I (Pol I) governs the transcription of ribosomal RNAs, which are needed for building and function of the ribosomes. These ribosynthetic activities are greatly increased in cancer cells, and Pol I transcription rate is commonly deregulated in human cancers....

Published: 3/13/2025 | Inventor(s): Marikki Laiho, Sara Sanders, Laureen Colis, James Barrow, Glen Ernst

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities